Gene · 2348
Papers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 3,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Enhanced PD-L1 targeting boosts the cytotoxic activity of FOLR1- CAR NK92 cells against ovarian cancer. | Cancer Immunol Immunother | 2026 | 42247058 | PubTator, text mining | PubMed |
| Histology-specific ADC target landscapes in ovarian cancer and therapy-associated antigen downshift after ADC exposure. | Gynecol Oncol | 2026 | 42235136 | PubTator, text mining | PubMed |
| Spatial, temporal, and molecular heterogeneity of ADC targets in high-grade serous ovarian carcinoma. | Br J Cancer | 2026 | 42231029 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in gynecologic cancers. | Cancer | 2026 | 42226034 | PubTator, text mining | PubMed |
| Medical treatment of autism spectrum disorder in children: Current evidence, controversies, and clinical challenges. | World J Clin Pediatr | 2026 | 42220936 | PubTator, text mining | PubMed |
| Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer. | Pharmaceutics | 2026 | 42198268 | PubTator, text mining | PubMed |
| Antibody-drug conjugates for primary brain tumors. | Front Oncol | 2026 | 42180101 | PubTator, text mining | PubMed |
| Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer. | Int J Gynecol Cancer | 2026 | 42172956 | PubTator, text mining | PubMed |
| Advancements in Intraoperative Imaging for Enhanced Surgical Precision. | Recent Results Cancer Res | 2026 | 42165837 | PubTator, text mining | PubMed |
| Statement of Retraction: Activation of cytotoxic T lymphocytes by self-differentiated myeloid-derived dendritic cells for killing breast cancer cells expressing folate receptor alpha protein. | Bioengineered | 2026 | 42165316 | PubTator, text mining | PubMed |
| Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α-Positive Advanced Ovarian Cancer. | Cancer Med | 2026 | 42165281 | PubTator, text mining | PubMed |
| Health economic evaluation of Mirvetuximab soravtansine for the treatment of FRα-positive, platinum resistant ovarian cancer in Germany. | J Cancer Res Clin Oncol | 2026 | 42162501 | PubTator, text mining | PubMed |
| Integrative Analysis of Cellular Senescence-Related Genes Identifies FOLR1 as a Novel Tumor Suppressor and a Potential Therapeutic Target in Lung Adenocarcinoma. | Cancers (Basel) | 2026 | 42122127 | PubTator, text mining | PubMed |
| Clinically relevant histopathological features and biomarkers in endometrial cancer. | Ceska Gynekol | 2026 | 42113616 | PubTator, text mining | PubMed |
| Prolonged disease-free survival with immunotherapy combined with chemotherapy in a patient with advanced stage large cell neuroendocrine carcinoma of the uterus. | Gynecol Oncol Rep | 2026 | 42111278 | PubTator, text mining | PubMed |
| Intracranial activity of mirvetuximab soravtansine in platinum-resistant high-grade serous ovarian cancer: Insights from a patient with central nervous system metastasis. | Gynecol Oncol Rep | 2026 | 42111277 | PubTator, text mining | PubMed |
| Association between maternal obesity and neonatal folate and vitamin B12 status: Functional biomarkers and placental transporters. | J Nutr Biochem | 2026 | 42097463 | PubTator, text mining | PubMed |
| HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract. | Int J Gynecol Pathol | 2026 | 42095344 | PubTator, text mining | PubMed |
| Case Report: Use of mirvetuximab soravtansine in a patient with platinum-resistant ovarian cancer and concomitant PARP-inhibitor-related myelodysplastic syndrome. | Front Oncol | 2026 | 42088210 | PubTator, text mining | PubMed |
| An exploration into the transplacental transfer of microplastics through placental transporters. | J Environ Sci (China) | 2026 | 42070857 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2348/papers?page=4